ASK REDCHAT ANYTHING ABOUT SAGIMET BIOSCIENCES INC.
Sagimet Biosciences Inc. (NASDAQ: SGMT)
Listen to this Section
$6.94
+0.0800
(
+1.17% )
212.2K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| Denifanstat w/ BevacizumabDetailsGlioblastoma |
Phase 3 |
| Denifanstat (ASC40)DetailsAcne |
Phase 3 |
| DenifanstatDetailsNon-alcoholic steatohepatitis |
Phase 3 |
| DenifanstatDetailsLiver disease |
Phase 1 |
Market Data
|
| Open |
$6.94 |
| Previous Close |
$6.86 |
| Volume |
212.2K |
| Market Cap |
$423.62M |
| Day Range |
$6.83 - $7.25 |
| 52 Week Range |
$3.83 - $11.41 |
| Shares Outstanding |
61.75M |
| Change % |
+1.17% |
| Net Change |
▲ 0.0800 |
| Insider Ownership |
-0.02% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | |
| IPO Year | 2023 |
| Country | United States |
| Underwriter | Goldman Sachs, TD Cowen, Piper Sandler, Citizens JMP, more |
Insider Ownership Transactions
Total Amount Purchased:
-6,468,882.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2023-12-08 |
Buy |
1600.00 |
Happel David |
| 2023-11-21 |
Sale |
-171420.00 |
Rozek Elizabeth |
| 2023-11-21 |
Sale |
-89570.00 |
Martins Eduardo Bruno |
| 2023-11-21 |
Sale |
-150750.00 |
Kemble George |
| 2023-11-21 |
Sale |
-624910.00 |
Happel David |
| 2023-11-20 |
Buy |
590.00 |
Happel David |
| 2023-09-08 |
Sale |
-5630.00 |
Kemble George |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| schedule |
Other |
1 |
Nov 14, 2025 |
| 8-k |
8K-related |
66 |
Nov 13, 2025 |
| 10-q |
Quarterly Reports |
55 |
Nov 13, 2025 |
| 4 |
Insider transactions |
1 |
Nov 06, 2025 |
| 8-k |
8K-related |
64 |
Oct 23, 2025 |
| 8-k |
8K-related |
13 |
Aug 22, 2025 |
| 8-k |
8K-related |
15 |
Aug 14, 2025 |
| 10-q |
Quarterly Reports |
62 |
Aug 13, 2025 |
| 8-k |
8K-related |
65 |
Aug 13, 2025 |
| 4 |
Insider transactions |
1 |
Jul 23, 2025 |